gti12b2563009.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
SEC
FILE NUMBER
000-22179
|
CUSIP
NUMBER
40171F
105
|
(Check One) oForm 10-K o Form 20-F o Form 11-K ýForm 10-Q o Form 10-Do Form N-SAR o Form N-CSR
For
Period Ended: June 30,
2009
[ ]
Transition Report on Form 10-K
[ ]
Transition Report on Form 20-F
[ ]
Transition Report on Form 11-K
[ ]
Transition Report on Form 10-Q
[ ]
Transition Report on Form N-SAR
For the
Transition Period Ended: ___________________
Read
Instruction (on back page) Before Preparing Form. Please Print or
Type.
|
Nothing
in this form shall be construed to imply that the Commission has verified
any information contained herein.
|
If the
notification relates to a portion of the filing checked above, identify the
Item(s) to which the notification relates:
PART
I -- REGISTRANT INFORMATION
________________
|
Full
Name of Registrant
|
Guided
Therapeutics, Inc.
|
Former
Name if Applicable
________________
|
Address
of Principal Executive Office (Street and
Number)
4955
Avalon Ridge Pkwy, Suite 300
|
City,
State and Zip Code
Norcross,
Georgia 30071
|
PART
II -- RULES 12b-25(b) AND (c)
If the
subject report could not be filed without unreasonable effort or expense and the
registrant seeks relief pursuant to Rule 12b-25(b), the following should be
completed. (Check box if appropriate) ý
(a) The
reasons described in reasonable detail in Part III of this form could not be
eliminated without unreasonable effort or expense;
(b) The
subject annual report, semi-annual report, transition report on Form 10-K, Form
20-F, Form 11-K, Form N-SAR or Form N-CSR or portion thereof, will be filed on
or before the fifteenth calendar day following the prescribed due date; or the
subject quarterly report or transition report on Form 10-Q, or subject
distribution report on form 10-D, or portion thereof, will be filed on or before
the fifth calendar day following the prescribed due date; and
(c) The
accountant's statement or other exhibit required by Rule 12b-25(c) has been
attached if applicable.
PART
III -- NARRATIVE
State
below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D,
N-SAR, N-CSR, or the transition report portion thereof, could not be filed
within the prescribed time period.
Guided
Therapeutics is in the process of preparing and reviewing the report on form
10-Q for the quarter ended June 30, 2009, and management does not believe the
Form 10-Q can be completed on or before the August 14, 2009 prescribed due date
without unreasonable effort or expense. The company's Form 10-Q for the quarter
ended June 30, 2009 will be filed as soon as practicable, but does currently
expect that it will be filed on or before the fifth calendar day following the
prescribed due date.
PART
IV-- OTHER INFORMATION
(1) Name
and telephone number of person to contact in regard to this
notification
Mark L. Faupel,
Ph.D.
(Name)
770
242-8723
(Area
Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or
15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period
that the registrant was required to file such report(s) been filed? If answer is
no, identify report(s). o Yes x No Form 10-Q1,
2009
(3) Is it
anticipated that any significant change in results of operations from the
corresponding period for the last fiscal year will be reflected by the earnings
statements to be included in the subject report or portion thereof?
o Yes x No
If so,
attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
Guided
Therapeutics, Inc.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto
duly authorized.
Date:
August 14, 2009
|
/S/
Mark L. Faupel, Ph.D.
|
|
|
By:
Mark L. Faupel, Ph. D.
Chief
Executive Officer & Chief Financial Officer
|
|
INSTRUCTION:
The form may be signed by an executive officer of the registrant or by any other
duly authorized representative. The name and title of the person signing the
form shall be typed or printed beneath the signature. If the statement is signed
on behalf of the registrant by an authorized representative (other than an
executive officer), evidence of the representative's authority to sign on behalf
of the registrant shall be filed with the form.
ATTENTION
Intentional
misstatements or omissions of fact constitute Federal Criminal Violations (See
18 U.S.C. 1001).
General
Instructions
1. This
form is required by Rule 12b-25 (17 CFR 240.12b-25) of the General Rules and
Regulations under the Securities Exchange Act of 1934.
2. One
signed original and four conformed copies of this form and amendments thereto
must be completed and filed with the Securities and Exchange Commission,
Washington, D.C. 20549, in accordance with Rule 0-3 of the General Rules and
Regulations under the Act. The information contained in or filed with the form
will be made a matter of public record in the Commission files.
3. A
manually signed copy of the form and amendments thereto shall be filed with each
national securities exchange on which any class of securities of the registrant
is registered.
4.
Amendments to the notifications must also be filed on Form 12b-25 but need not
restate information that has been correctly furnished. The form shall be clearly
identified as an amended notification.
5.
Electronic filers. This form shall not be used by electronic filers unable to
timely file a report solely due to electronic difficulties. Filers unable to
submit a report within the time period prescribed due to difficulties in
electronic filing should comply with either Rule 201 or Rule 202 of Regulation
S-T (§232.201 or §232.202 of this chapter) or apply for an adjustment in filing
date pursuant to Rule 13(b) of Regulation S-T (§232.13(b) of this
Chapter).